Pincet Laurence, Fanchette Aurelie, Elmers Jolanda, Bourhis Jean, Lambercy Karma, Romano Edouard
ENT, Head and Neck Department, CHUV, Rue du Bugnon 46, 1010 Lausanne, Switzerland.
Pole Formation, Recherches-Soutien aux Revus Systématiques, Bibliothèque Universitaire de Médecine, Chemin des Falaises 2, 1005 Lausanne, Switzerland.
Cancers (Basel). 2025 Jun 24;17(13):2124. doi: 10.3390/cancers17132124.
Intraoperative radiotherapy (IORT) has been used for decades to improve local control in advanced and recurrent head and neck cancers by delivering a concentrated dose of radiation directly to the tumor bed during surgery. Despite its potential advantages, IORT remains controversial due to its high complication rates and logistical complexity. This systematic review aims to assess the current evidence on IORT in head and neck oncology, evaluating its indications, effectiveness, and limitations. A systematic literature review was conducted in accordance with Cochrane systematic review method and reported following PRISMA guidelines. Databases, including Medline, Embase, Cochrane, and Web of Science, were searched for studies evaluating IORT in head and neck cancer. Outcomes of interest included local control rates, overall survival, complications, and treatment logistics. Data were weighted based on patient numbers, and statistical analyses included weighted means and comparative tests. Included in this review are 47 studies that included 2330 patients. The studies were highly heterogeneous, limiting definitive conclusions. IORT was mainly used in stage III/IV or recurrent tumors, with an average dose of 14.7 Gy (range: 1-40 Gy). The five-year local control was 47% to 82%. Complication rates included wound necrosis (22,3%), fistulas 34 (17.8%), and carotid blow-out (14.5%). Logistical constraints remain a major limitation. The heterogeneous data and logistic challenges of IORT in head and neck oncology have limited its use, and the benefits remain uncertain.
术中放疗(IORT)已被使用数十年,通过在手术期间直接向肿瘤床给予集中剂量的辐射,来提高晚期和复发性头颈癌的局部控制率。尽管具有潜在优势,但由于其高并发症发生率和后勤复杂性,IORT仍然存在争议。本系统评价旨在评估头颈肿瘤学中IORT的现有证据,评估其适应症、有效性和局限性。按照Cochrane系统评价方法进行了系统的文献综述,并按照PRISMA指南进行报告。检索了包括Medline、Embase、Cochrane和科学网在内的数据库,以查找评估头颈癌IORT的研究。感兴趣的结果包括局部控制率、总生存率、并发症和治疗后勤。根据患者数量对数据进行加权,统计分析包括加权均值和比较检验。本综述纳入了47项研究,共2330例患者。这些研究具有高度异质性,限制了得出确定性结论。IORT主要用于III/IV期或复发性肿瘤,平均剂量为14.7 Gy(范围:1-40 Gy)。五年局部控制率为47%至82%。并发症发生率包括伤口坏死(22.3%)、瘘管(17.8%)和颈动脉破裂(14.5%)。后勤限制仍然是一个主要局限。IORT在头颈肿瘤学中的数据异质性和后勤挑战限制了其应用,其益处仍不确定。